RU2002107998A - Сульфонилкарбоксамидные производные, способ их получения и их применение в качестве лекарственных средств - Google Patents
Сульфонилкарбоксамидные производные, способ их получения и их применение в качестве лекарственных средств Download PDFInfo
- Publication number
- RU2002107998A RU2002107998A RU2002107998/04A RU2002107998A RU2002107998A RU 2002107998 A RU2002107998 A RU 2002107998A RU 2002107998/04 A RU2002107998/04 A RU 2002107998/04A RU 2002107998 A RU2002107998 A RU 2002107998A RU 2002107998 A RU2002107998 A RU 2002107998A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- conh
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Соединения формулы I
где X, R1, R2, R3 независимо друг от друга означают NR6R7, (СН2)-пиридил, (СН2)n-фенил, причем n может означать 0-6 и фенильный остаток может быть вплоть до двукратно замещен F, Cl, Br, CF3, NH2, CN, OCF3, О(C1-С6)-алкилом, S(C1-C6)-алкилом, (C1-C6)-алкилом, (С3-С6)-циклоалкилом, COO-(C1-C6)-алкилом, СОО(С3-С6)-циклоалкилом, CONH2, CONH-(C1-C6)-алкилом, CON-[(C1-C6)-алкил]2;
(C1-C8)-алкил, пирролидинил, пиперидинил, пиперазинил, пиперазинил-2-он, морфолинил, тетрагидропиридинил, тетрагидрохинолинил, тетрагидроизохинолинил, причем циклы, смотря по обстоятельствам, могут быть замещены фенилом, (C1-C6)-алкилфенилом, -ОН, (C1-C6)-алкилом, (C1-C6)-алкил-ОН, O-фенилом, 3-фенилом, (СО)-(C1-C6)-алкилом, (СО)-фенилом, причем фенильный заместитель незамещен или вплоть до двукратно замещен F, Cl, Br, ОН, CF3, CN, OCF3, О-(C1-C6)-алкилом, S-(C1-C6)-алкилом, SO(C1-C6)-алкилом, SO2(C1-C6)-алкилом, (C1-C6)-алкилом, (С3-С6)-циклоалкилом, СООН, СОО-(C1-C6)-алкилом, СОО-(С3-С6)-циклоалкилом, CONH2, CONH-(C1-C6)-алкилом, CON[(C1-C6)-алкил]2, CONH-(С3-С6)-циклоалкилом, NH2, NHCO-(C1-C6)-алкилом, NHCO-фенилом;
R6 и R7, независимо друг от друга, означают атом водорода, (C1-C6)-алкил, (C1-C6)-алкил-ОН, (C1-C6)-алкил-NH2, (C1-C6)-алкил-O-(C1-C6)-алкил, О-(C1-C6)-алкил, (С3-С6)-циклоалкил, СО-(C1-C6)-алкил, (C1-C6)-anKHA-NH-C(O)-(C1-C6)-алкил, (C1-C6)-алкил-NH-(C1-C6)-алкил, (C1-C6)-алкил-N[(C1-C6)-алкил]2, (C1-C6)-алкил-O-фенил, СНО, СО-фенил;
(СН2)n-Ar, причем n может означать 0-6 и Ar может означать фенил, бифенил, 1- или 2-нафтил, 1- или 2-тетрагидрофуранил, 2-, 3 или 4-пиридил, 2- или 3-тиенил, 2- или 3-фурил, 2-, 4- или 5-тиазолил, 2-, 4- или 5-оксазолил, 1-пиразолил, 3-, 4- или 5-изоксазолил, (С3-С6)-циклоалкил, пиперидинил, пирролидинил, оксопиридинил, 2- или 3-пирролил, 2- или 3-пиридазинил, 2-, 4- или 5-пиримидинил, 2-пиразинил, 2-(1,3,5-триазинил), 2-, 3- или 4-морфолинил, 2- или 5-бензимидазолил, 2-бензотиазолил, 1,2,4-триазол-3-ил, 1,2,4-триазол-5-ил, тетразол-5-ил, индол-3-ил, индол-5-ил или N-метилимидазол-2-, -4- или -5-ил и Ar вплоть до двукратно может быть замещен F, Cl, Br, ОН, CF3, NO2, CN, OCF3, O-CH2-O, O-(C1-C6)-алкилом, S-(C1-C6)-алкилом, SO(C1-C6)-алкилом, SO2-(C1-C6)-алкилом, (C1-C6)-алкилом, (С3-С6)-циклоалкилом, СООН, СОО-(C1-C6)-алкилом, СОО(С3-С6)-циклоалкилом, CONH2, CONH-(C1-C6)-алкилом, CON[(C1-C6)-алкил]2, CONH(С3-С6)-циклоалкилом, NH2, NHCO-(C1-C6)-алкилом, NHCO-фенилом, пирролидин-1-илом, морфолин-1-илом, пиперидин-1-илом, пиперазин-1-илом, 4-метилпиперазин-1-илом, (СН2)n-фенилом, О-(СН2)n-фенилом, S-(СН2)п-фенилом, SO2(СН2)n-фенилом, причем n=0-3;
а также их физиологически приемлемые соли.
2. Соединения формулы (I) по п.1, отличающиеся тем, что в формуле (I) R1, R2 независимо друг от друга означают NR6R7, пирролидинил, пиперидинил, пиперазинил, тетрагидропиридинил, причем циклы, смотря по обстоятельствам, могут быть замещены фенилом, (C1-C6)-алкилфенилом, (C1-C6)-алкилом, (C1-C6)-алкил-ОН, O-фенилом, S-фенилом, (СО) (C1-C6)-алкилом, (СО)-фенилом, причем фенильный заместитель незамещен или вплоть до двукратно замещен F, Cl, Br, CF3, CN, OCF3, О-(C1-C6)-алкилом, S-(C1-C6)-алкилом, (C1-C6)-алкилом, (С3-С6)-циклоалкилом, СООН, COO-(C1-C6)-алкилом, СОО(С3-С6)-циклоалкилом, CONH2, CONH-(C1-C6)-алкилом, CON-[(C1-C6)-алкил]2, NH2, NHCO-(C1-C6)-алкилом, NHCO-фенилом;
R6, R7 независимо друг от друга означают атом водорода, (C1-C6)-алкил, (C1-C6)-алкил-O(C1-C6)-алкил, (С3-С6)-циклоалкил, СО(C1-C6)-алкил, (C1-C6)-алкил-NH-C(О)(C1-C6)-алкил, (C1-C6)-алкил-NH(C1-C6)-алкил, (C1-C6)-алкил-N[(C1-C6)-алкил]2;
(CH2)n-Ar, причем n может означать 0-6 и Ar может означать фенил, бифенил, 1- или 2-нафтил, 2-, 3- или 4-пиридил, 2- или 3-тиенил, 2-, 4- или 5-тиазолил, 2-, 4- или 5-оксазолил, 3- или 5-изоксазолил, (С3-С6)-циклоалкил, пиперидинил, пирролидинил, 2-, 4- или 5-пиримидинил, 2-, 3- или 4-морфолинил, 2- или 5-бензимидазолил, 2-бензотиазолил или индол-3-ил, индол-5-ил; и Ar вплоть до двукратно может быть замещен F, C1, Br, ОН, CF3, NO2, CN, OCF3, О-(C1-C6)-алкилом, S-(C1-C6)-алкилом, SO-(C1-C6)-алкилом, SO2(C1-C6)-алкилом, (C1-C6)-алкилом, (С3-С6)-циклоалкилом, СООН, COO-(C1-C6)-алкилом, СОО-(С3-С6)-циклоалкилом, CONH2, CONH-(C1-C6)-алкилом, NH2, NHCO-фенилом, (CH2)n-фенилом, О(СН2)n-фенилом, S(СН2)n-фенилом, причем n=0-3;
X, R3 независимо друг от друга означают NR8R9, пирролидинил, пиперидинил, морфолинил, (C1-C6)-алкил, (СН2)n-фенил, причем n может означать 0-6 и фенильный остаток может быть вплоть до двукратно замещен F, Cl, Br, CF3, CN, OCF3, O-(C1-С6)-алкилом, S(C1-C6)-алкилом, (C1-C6)-алкилом, (С3-С6)-циклоалкилом, СОО-(C1-C6)-алкилом, СОО-(С3-С6)-циклоалкилом, CONH2, CONH(C1-C6)-алкилом, CON-[(C1-C6)-алкил]2;
R8, R9 независимо друг от друга, означают атом водорода, (C1-C6)-алкил, (С3-С6)-циклоалкил, СО-(C1-C6)-алкил, (C1-C6)-алкил-СО-(C1-C6)-алкил, SO2-бензил, SO2-бензил-ОСН3, (CH2)n-Ar, причем n может означать 0-6 и Ar может означать фенил или тиенил и Ar вплоть до двукратно может быть замещен F, Cl, Br, CF3, NO2, CN, OCF3, O-СН2-О, О-(C1-C6)-алкилом, S-(C1-C6)-алкилом, SO(C1-C6)-алкилом, SO2(C1-C6)-алкилом, (C1-C6)-алкилом, (С3-С6)-циклоалкилом, NHCO-фенилом, (СН2)n-фенилом, O-(СН2)n-фенилом, S(СН2)n-фенилом, SO2-(СН2)n-фенилом, причем n=0-2;
а также их физиологически приемлемые соли.
3. Соединения формулы (I) по п.1 или 2, отличающиеся тем, что в формуле (I) R1, R2 независимо друг от друга означают NR6R7, пиперидинил, пиперазинил, тетрагидропиридинил, причем циклы, смотря по обстоятельствам, могут быть замещены фенилом, (C1-C6)-алкилфенилом, (C1-C6)-алкилом, (СО)-(C1-C6)-алкилом;
R6, R7 независимо друг от друга означают атом водорода, (C1-C6)-алкил, (C1-C6)-алкил-NH-(C1-C6)-алкил, (C1-C6)-алкил-N[(C1-C6)-алкил]2;
(CH2)n-Ar, причем n может означать 0-6 и Ar может означать фенил, 2-, 3- или 4-пиридил, пиперидинил, пирролидинил, 2-, 4- или 5-пиримидинил, 2-, 3- или 4-морфолинил, и Ar вплоть до двукратно может быть замещен F, Cl, Br, ОН, CF3, NO2, CN, OCF3, О-(C1-C6)-алкилом, (C1-C6)-алкилом, СООН, NH2, (CH2)n-фенилом, причем n=0-3;
Х означает NR8R9, пиперазинил, (C1-C6)-алкил, (СН2)n-фенил, причем n может означать 0-6;
R3 означает NR10R11, пиперазинил;
R8, R9 независимо друг от друга означают атом водорода, (C1-C6)-алкил, (С3-С6)-циклоалкил, СО-(C1-C6)-алкил, (C1-C6)-алкил-СО-(C1-C6)-алкил, SO2-бензил, SO2-бензил-ОСН3, (СН2)n-Ar, причем n может означать 0-6 и Ar может означать фенил или тиенил;
R10, R11 независимо друг от друга означают атом водорода, (C1-C6)-алкил, (С3-С6)-циклоалкил, СО-(C1-C6)-алкил, (C1-C6)-алкил-СО-(C1-C6)-алкил, SO2-бензил, SO2-бензил-ОСН3, (СН2)n-Ar, причем n может означать 0-6 и Ar может означать фенил или тиенил;
а также их физиологически приемлемые соли.
4. Соединения формулы (I) по одному или нескольким из пп.1-3, отличающиеся тем, что в формуле (I) R1, R2 независимо друг от друга означают NR6R7, пиперидинил, пиперазинил, тетрагидропиридинил, причем циклы, смотря по обстоятельствам, могут быть замещены фенилом, (C1-C6)-алкилфенилом, (C1-C6)-алкилом, (СО) (C1-C6)-алкилом;
R6, R7 независимо друг от друга означают атом водорода, (C1-C6)-алкил, (C1-C6)-алкил-NH-(C1-C6)-алкил, (C1-C6)-алкил-N-[(C1-C6)-алкил]2;
(СН2)n-Ar, причем n может означать 0-6 и Ar может означать фенил, 2-, 3- или 4-пиридил, пиперидинил, пирролидинил, 2-, 4- или 5-пиримидинил, 2-, 3- или 4-морфолинил, и Ar вплоть до двукратно может быть замещен F, Cl, Br, ОН, CF3, NO2, CN, OCF3, О(C1-C6)-алкилом, (C1-C6)-алкилом, СООН, NH2, (СН2)n-фенилом, причем n может означать 0-3;
Х означает (C1-C6)-алкил, (СН2)n-фенил, причем n может означать 0-6;
R3 означает NR10R11, пиперазинил;
R10, R11 независимо друг от друга означают атом водорода, (C1-C6)-алкил, (С3-С6)-циклоалкил, СО-(C1-C6)-алкил, (C1-C6)-алкил-СО-(C1-C6)-алкил, SO2-бензил, SO2-бензил-ОСН3, (СН2)n-Ar, причем n может означать 0-6 и Ar может означать фенил или тиенил;
а также их физиологически приемлемые соли.
5. Лекарственное средство, содержащее одно или несколько соединений по одному или нескольким из пп.1-4.
6. Лекарственное средство по п.5, отличающееся тем, что оно дополнительно содержит одно или несколько средств, понижающих уровень липидов в крови.
7. Соединения по одному или нескольким из пп.1-4, пригодные в качестве лекарственного средства для лечения гиперлипидемии.
8. Соединения по одному или нескольким из пп.1-4, пригодные в качестве лекарственного средства для лечения артериосклероза.
9. Способ получения лекарственного средства, содержащего одно или несколько соединений по одному или нескольким из пп.1-4, отличающийся тем, что биологически активное вещество смешивают с фармацевтически пригодным носителем и эту смесь доводят до пригодной для введения формы.
10. Применение соединений по одному или нескольким из пп.1-4 для получения лекарственного средства для лечения гиперлипидемии.
11. Применение соединений по одному или нескольким из пп.1-4 для получения лекарственного средства для лечения артериосклероза.
12. Способ получения соединений по одному или нескольким из пп.1-4, отличающийся тем, что согласно следующей схеме:
соединение формулы (II), где Х и R3 имеют указанные для формулы (I) значения и Hall и На12, соответственно, означают атом галогена, вводят во взаимодействие с соединением R2-H, где R2 имеет указанное для формулы (I) значение, с получением соединения формулы (III) и это соединение вводят во взаимодействие с соединением R1-H, где R1 имеет указанное для формулы (I) значение, с получением соединения формулы (I) и его, в случае необходимости, с помощью кислоты превращают в фармакологически приемлемую соль.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19941540.4 | 1999-09-01 | ||
DE1999141540 DE19941540C2 (de) | 1999-09-01 | 1999-09-01 | Sulfonylcarboxamide zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidämie |
DE2000127611 DE10027611A1 (de) | 2000-06-06 | 2000-06-06 | Sulfonylcarboxamidderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10027611.3 | 2000-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2002107998A true RU2002107998A (ru) | 2003-11-10 |
Family
ID=26005953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002107998/04A RU2002107998A (ru) | 1999-09-01 | 2000-08-17 | Сульфонилкарбоксамидные производные, способ их получения и их применение в качестве лекарственных средств |
Country Status (28)
Country | Link |
---|---|
US (2) | US6342512B1 (ru) |
EP (1) | EP1218341B1 (ru) |
JP (1) | JP4792186B2 (ru) |
KR (1) | KR20020033778A (ru) |
CN (1) | CN1372541A (ru) |
AR (1) | AR025444A1 (ru) |
AT (1) | ATE302754T1 (ru) |
AU (1) | AU774071B2 (ru) |
BR (1) | BR0013727A (ru) |
CA (1) | CA2383781A1 (ru) |
CO (1) | CO5190698A1 (ru) |
CZ (1) | CZ2002767A3 (ru) |
DE (1) | DE50011035D1 (ru) |
DK (1) | DK1218341T3 (ru) |
EE (1) | EE200200095A (ru) |
ES (1) | ES2246247T3 (ru) |
HK (1) | HK1048984A1 (ru) |
HR (1) | HRP20020177A2 (ru) |
HU (1) | HUP0202472A3 (ru) |
IL (1) | IL148148A0 (ru) |
MX (1) | MXPA02001696A (ru) |
MY (1) | MY133732A (ru) |
NO (1) | NO20020811L (ru) |
PL (1) | PL353367A1 (ru) |
PT (1) | PT1218341E (ru) |
RU (1) | RU2002107998A (ru) |
SK (1) | SK2682002A3 (ru) |
WO (1) | WO2001016094A1 (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2485097C2 (ru) * | 2007-09-26 | 2013-06-20 | Джонс Хопкинс Юниверсити | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила |
RU2616292C2 (ru) * | 2006-03-17 | 2017-04-14 | Дзе Джонс Хопкинс Юниверсити | Производные n-гидроксилсульфонамида в качестве новых физиологически полезных доноров нитроксила |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10112040A1 (de) * | 2001-03-14 | 2002-10-02 | Aventis Pharma Gmbh | Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten |
US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
CN1329382C (zh) | 2001-05-11 | 2007-08-01 | 比奥维特罗姆股份公司 | 治疗肥胖、ⅱ型糖尿病和cns-疾病的芳基磺酰胺化合物 |
AU2002333373B2 (en) * | 2001-08-22 | 2006-12-14 | Sanofi-Aventis Deutschland Gmbh | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof |
JP4436129B2 (ja) | 2001-08-31 | 2010-03-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ジアリールシクロアルキル誘導体、その製造法及びppar−活性剤としてのその使用 |
US7399777B2 (en) * | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
US6884812B2 (en) | 2001-08-31 | 2005-04-26 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals |
ATE473005T1 (de) * | 2002-03-13 | 2010-07-15 | Janssen Pharmaceutica Nv | Histone-deacetylase-inhibitoren |
US7078404B2 (en) * | 2002-04-11 | 2006-07-18 | Sanofi-Aventis Deutschland Gmbh | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use |
US7223796B2 (en) * | 2002-04-11 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
US7049341B2 (en) * | 2002-06-07 | 2006-05-23 | Aventis Pharma Deutschland Gmbh | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use |
US7262220B2 (en) * | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
CN1304371C (zh) * | 2002-07-12 | 2007-03-14 | 塞诺菲-安万特德国有限公司 | 杂环取代的苯甲酰脲、其药物和制备药物的用途 |
US20040157922A1 (en) * | 2002-10-04 | 2004-08-12 | Aventis Pharma Deutschland Gmbh | Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments |
US7208504B2 (en) * | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
DE10258007B4 (de) * | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
US7179941B2 (en) * | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7196114B2 (en) * | 2003-02-17 | 2007-03-27 | Sanofi-Aventis Deutschland Gmbh | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use |
US7148246B2 (en) * | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
DE10308351A1 (de) * | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10308355A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE10308352A1 (de) * | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
US7173151B2 (en) * | 2003-02-27 | 2007-02-06 | Sanofi-Aventisdeutschand Gmbh | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals |
US7501440B2 (en) * | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
DE10314610A1 (de) * | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
US7008957B2 (en) * | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094800B2 (en) * | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7094794B2 (en) * | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (de) * | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
US7241787B2 (en) * | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
US7470706B2 (en) * | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
US7498341B2 (en) * | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
US7402674B2 (en) * | 2004-01-31 | 2008-07-22 | Sanofi-Aventis Deutschland Gmbh, | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
DE102004005172A1 (de) * | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
EP1586573B1 (en) | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
JP4904026B2 (ja) * | 2004-08-04 | 2012-03-28 | 日本曹達株式会社 | 光反応性有機薄膜を形成する新規化合物及び有機薄膜形成体 |
DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
AU2006299091A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
PL2383271T3 (pl) * | 2006-03-13 | 2013-12-31 | Kyorin Seiyaku Kk | Aminochinolony jako inhibitory GSK-3 |
DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
DE102007002260A1 (de) * | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP4891111B2 (ja) * | 2007-02-16 | 2012-03-07 | 富士フイルム株式会社 | ズームレンズ |
DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
ES2340640T3 (es) | 2007-03-23 | 2010-06-07 | Icagen, Inc. | Inhibidores de canales de iones. |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
KR101563018B1 (ko) * | 2007-09-11 | 2015-10-23 | 교린 세이야꾸 가부시키 가이샤 | Gsk-3 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론 |
CN101855229A (zh) | 2007-09-12 | 2010-10-06 | 埃迪威克斯生物科学公司 | 作为gsk-3抑制剂的螺环状氨基喹诺酮 |
DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2406266B1 (en) | 2009-03-11 | 2013-12-25 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones as gsk-3 inhibitors |
CA2771278A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2482823A2 (en) | 2009-10-02 | 2012-08-08 | Sanofi | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9048420B2 (en) * | 2011-10-03 | 2015-06-02 | Seiko Epson Corporation | Power generation unit, electronic apparatus, transportation device, and method of controlling power generation unit |
FR2997247B1 (fr) * | 2012-10-22 | 2016-12-09 | Commissariat Energie Atomique | Generateur d'electricite et recuperateur d'energie |
CN104502513B (zh) * | 2015-01-14 | 2016-04-06 | 中国矿业大学连云港徐圩新区高新技术研究院 | 一种对羧基苯磺酰胺的高效液相色谱测定方法 |
PE20180783A1 (es) | 2015-08-07 | 2018-05-07 | Bayer Cropscience Ag | Derivados heterociclicos condensados sustituidos por 2-(het) arilo como pesticidas |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1353357A (en) * | 1970-09-14 | 1974-05-15 | Pfizer | Substituted 5-sulphamylbenzoic acids |
US4138399A (en) | 1970-09-14 | 1979-02-06 | Pfizer Inc. | Sulfamylbenzoic acid |
DE2517183A1 (de) * | 1975-04-18 | 1976-10-28 | Hoechst Ag | Basisch substituierte 5-sulfamoyl- anthranilsaeurederivate und verfahren zu ihrer herstellung |
-
2000
- 2000-08-17 HU HU0202472A patent/HUP0202472A3/hu unknown
- 2000-08-17 KR KR1020027002650A patent/KR20020033778A/ko not_active Application Discontinuation
- 2000-08-17 BR BR0013727-8A patent/BR0013727A/pt not_active IP Right Cessation
- 2000-08-17 CZ CZ2002767A patent/CZ2002767A3/cs unknown
- 2000-08-17 CA CA002383781A patent/CA2383781A1/en not_active Abandoned
- 2000-08-17 JP JP2001519664A patent/JP4792186B2/ja not_active Expired - Fee Related
- 2000-08-17 PT PT00953172T patent/PT1218341E/pt unknown
- 2000-08-17 IL IL14814800A patent/IL148148A0/xx unknown
- 2000-08-17 RU RU2002107998/04A patent/RU2002107998A/ru not_active Application Discontinuation
- 2000-08-17 DE DE50011035T patent/DE50011035D1/de not_active Expired - Lifetime
- 2000-08-17 CN CN00811269A patent/CN1372541A/zh active Pending
- 2000-08-17 EE EEP200200095A patent/EE200200095A/xx unknown
- 2000-08-17 PL PL00353367A patent/PL353367A1/xx not_active Application Discontinuation
- 2000-08-17 AT AT00953172T patent/ATE302754T1/de not_active IP Right Cessation
- 2000-08-17 EP EP00953172A patent/EP1218341B1/de not_active Expired - Lifetime
- 2000-08-17 DK DK00953172T patent/DK1218341T3/da active
- 2000-08-17 AU AU65712/00A patent/AU774071B2/en not_active Ceased
- 2000-08-17 MX MXPA02001696A patent/MXPA02001696A/es unknown
- 2000-08-17 SK SK268-2002A patent/SK2682002A3/sk unknown
- 2000-08-17 WO PCT/EP2000/008027 patent/WO2001016094A1/de active IP Right Grant
- 2000-08-17 ES ES00953172T patent/ES2246247T3/es not_active Expired - Lifetime
- 2000-08-25 CO CO00063853A patent/CO5190698A1/es not_active Application Discontinuation
- 2000-08-29 MY MYPI20003962 patent/MY133732A/en unknown
- 2000-08-30 AR ARP000104517A patent/AR025444A1/es unknown
- 2000-09-01 US US09/654,841 patent/US6342512B1/en not_active Expired - Lifetime
-
2001
- 2001-09-27 US US09/963,380 patent/US6552048B2/en not_active Expired - Lifetime
-
2002
- 2002-02-19 NO NO20020811A patent/NO20020811L/no not_active Application Discontinuation
- 2002-02-27 HR HR20020177A patent/HRP20020177A2/hr not_active Application Discontinuation
-
2003
- 2003-02-18 HK HK03101152.9A patent/HK1048984A1/zh unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2616292C2 (ru) * | 2006-03-17 | 2017-04-14 | Дзе Джонс Хопкинс Юниверсити | Производные n-гидроксилсульфонамида в качестве новых физиологически полезных доноров нитроксила |
US11306056B2 (en) | 2006-03-17 | 2022-04-19 | Cardioxyl Pharmaceuticals, Inc. | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
RU2485097C2 (ru) * | 2007-09-26 | 2013-06-20 | Джонс Хопкинс Юниверсити | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила |
Also Published As
Publication number | Publication date |
---|---|
IL148148A0 (en) | 2002-09-12 |
US6552048B2 (en) | 2003-04-22 |
EP1218341A1 (de) | 2002-07-03 |
CZ2002767A3 (cs) | 2002-06-12 |
AU774071B2 (en) | 2004-06-17 |
CN1372541A (zh) | 2002-10-02 |
JP2003508380A (ja) | 2003-03-04 |
EE200200095A (et) | 2003-04-15 |
ES2246247T3 (es) | 2006-02-16 |
PT1218341E (pt) | 2005-11-30 |
JP4792186B2 (ja) | 2011-10-12 |
NO20020811D0 (no) | 2002-02-19 |
CO5190698A1 (es) | 2002-08-29 |
MXPA02001696A (es) | 2002-08-06 |
CA2383781A1 (en) | 2001-03-08 |
SK2682002A3 (en) | 2002-07-02 |
HRP20020177A2 (en) | 2004-02-29 |
MY133732A (en) | 2007-11-30 |
HUP0202472A2 (hu) | 2002-12-28 |
NO20020811L (no) | 2002-04-30 |
EP1218341B1 (de) | 2005-08-24 |
US6342512B1 (en) | 2002-01-29 |
US20020072520A1 (en) | 2002-06-13 |
DE50011035D1 (de) | 2005-09-29 |
AU6571200A (en) | 2001-03-26 |
ATE302754T1 (de) | 2005-09-15 |
DK1218341T3 (da) | 2005-12-12 |
PL353367A1 (en) | 2003-11-17 |
WO2001016094A1 (de) | 2001-03-08 |
KR20020033778A (ko) | 2002-05-07 |
HK1048984A1 (zh) | 2003-04-25 |
AR025444A1 (es) | 2002-11-27 |
BR0013727A (pt) | 2002-05-07 |
HUP0202472A3 (en) | 2005-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002107998A (ru) | Сульфонилкарбоксамидные производные, способ их получения и их применение в качестве лекарственных средств | |
RU2001111750A (ru) | Производные индено-, нафто- и бензоциклогепта-дигидротиазола, их получение и применение в качестве анорексических лекарственных средств | |
US7807681B2 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
EP0771200B1 (en) | Use of raloxifene and its analogs for the manufacture of a medicament for the treatment of viral diseases | |
RU2217427C2 (ru) | Полициклические дигидротиазолы, анорексическое лекарственное средство и способ его получения | |
RU2002125460A (ru) | ЗАМЕЩЕННЫЕ В ПОЛОЖЕНИИ 8а ПРОИЗВОДНЫЕ 8,8а-ДИГИДРОИНДЕНО [1,2-d] ТИАЗОЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, НАПРИМЕР, В КАЧЕСТВЕ, АНОРЕКСИЧЕСКИХ СРЕДСТВ | |
JPH07196499A (ja) | 更年期症候群の治療法 | |
RU97107338A (ru) | Новые соединения | |
RU2002125673A (ru) | ПРОИЗВОДНЫЕ 8,8а-ДИГИДРОИНДЕНО [1,2-d]ТИАЗОЛА, СОДЕРЖАЩИЕ В ПОЛОЖЕНИИ 2 ЗАМЕСТИТЕЛЬ С СУЛЬФОНАМИДНОЙ ИЛИ СУЛЬФОНОВОЙ СТРУКТУРОЙ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА | |
ES2215270T3 (es) | Inhibicion de productos terminales de glicosilacion avanzada. | |
JPH07149644A (ja) | 血管形成および血管形成性疾患を抑制する方法 | |
JPH07188015A (ja) | 子宮線維症を抑制する方法 | |
CN111356456A (zh) | 2-芳基磺酰胺基-iV-芳基乙酰胺衍生的Stat3抑制剂 | |
JPH07196500A (ja) | 閉経期後症候群に関連する血管運動症状および併発性心理的障害を抑制するための医薬組成物 | |
JP2011509282A5 (ru) | ||
JPH07196502A (ja) | 閉経期後の女性におけるcns障害を抑制するための医薬組成物 | |
EP0337136A3 (en) | Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy | |
JPH07215857A (ja) | 性的早熟の抑制法 | |
JP2002529497A5 (ru) | ||
JP4982021B2 (ja) | 高脂血症の予防または治療用薬剤の製造のためのビススルホンアミドの使用 | |
EA000680B1 (ru) | Способ ингибирования меланомы | |
JPH10506111A (ja) | タモキシフェンおよびタモキシフェン類縁体の向子宮効果を削減する方法 | |
KR19990064099A (ko) | 플라스미노겐 활성인자 억제물질 1의 억제 방법 | |
US4755520A (en) | Spartein compounds, their preparation and use | |
RU2002114697A (ru) | Производные индено-, нафто- и бензоциклогептадигидротиазола, их получение и их применение в качестве анорексических лекарственных средств |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20050708 |